After Lybalvi’s Solid Early Launch, Alkermes Touts Neuropsychiatry Potential
Executive Summary
Alkermes tells J.P. Morgan audience it hopes new combo Lybalvi and established Aristada will boost each other and the neuropsychiatric franchise. But the firm noted its addiction drug Vivitrol requires complicated commercial plan.
You may also be interested in...
Alkermes Thinks Nemvaleukin Could Succeed Where Other IL-2 Candidates Have Failed
On the heels of clinical failures for Nektar’s pegylated IL-2 candidate bempeg, Alkermes’ CEO argued its high-dose IL-2 for cancer is well differentiated during earnings call. Schizophrenia drug Lybalvi posted solid first full-quarter revenue, prescription numbers.
New National Security Checks Could Hinder Investment, Warns UK Biotech Sector
Life science SMEs and their investors need to comply with new UK government checks on their dealmaking.
Alkermes Cites IL-2 Differentiation As It Moves To Phase III, And Seeks A Partner
Executives pointed to the IL-2 variant drug’s potential for subcutaneous administration as a key differentiator from other IL-2 variant programs.